Table 4.
Multivariable Linear Mixed-Effects Model for MMSE Score Change Over Time in both Intent-to-Treat (ITT) Study Population and EGFR-Mutant Subgroup
| Parameter (reference level) | Estimate | SE | P-value | 95% CI |
|---|---|---|---|---|
| ITT population | ||||
| Intercept | −0.67 | 0.83 | .421 | −2.30 to 0.96 |
| WBRT + erlotinib | 0 | 0 | - | - |
| WBRT | −0.56 | 0.32 | .080 | −1.20 to 0.07 |
| Time, mo | −0.02 | 0.09 | .861 | −0.19 to 0.16 |
| EGFR-mutant subgroup | ||||
| Intercept | 1.00 | 0.97 | .305 | −0.91 to 2.91 |
| WBRT + erlotinib | 0 | 0 | - | - |
| WBRT | −0.36 | 0.38 | .343 | −1.10 to 0.38 |
| Time, mo | −0.16 | 0.10 | .121 | −0.35 to 0.04 |
Abbreviations: MMSE, Folstein Mini-Mental State Examination; WBRT, whole-brain radiotherapy; ITT, Intent-to-Treat; EGFR, epithelial growth factor receptor.